Robert J. Soiffer, MD

Robert J. Soiffer, MD

Medical Oncology

Contact Information

Office Phone Number

617-632-6256

Fax

617-632-5175

Appointments

617-632-5138 (new)

Biography

Robert J. Soiffer, MD

Dr. Soiffer graduated from New York University School of Medicine in 1983, and trained in internal medicine at Brigham and Women's Hospital, where he also was chief medical resident. He joined DFCI in 1988, after completing a medical oncology fellowship. He is currently chief of the Division of Hematologic Malignancies and codirector of the Adult Stem Cell Transplantation Program. Dr. Soiffer is chairman of the Center for International Blood and Marrow Transplant Research advisory committee and has served as vice president (2006), president (2007), and immediate past president (2008) of the American Society of Blood and Marrow Transplantation.

Researcher

Physician

Chair, Executive Committee for Clinical Programs
Vice Chair, Department of Medical Oncology
Chief, Division of Hematologic Malignancies
Institute Physician
Worthington and Margaret Collette Professor of Medicine in the Field of Hematologic Oncology, Harvard Medical School

Centers/Programs

Stem Cell Transplantation

Clinical Interests

Chronic lymphocytic leukemia, Leukemias, Lymphoma, Stem cell/bone marrow transplantation

Board Certification

  • Internal Medicine, 1986
  • Medical Oncology, 1989

Fellowship

  • Dana-Farber Cancer Institute, Hematology & Oncology

Residency

  • Brigham and Women's Hospital, Chief Medical Resident
  • Brigham and Women's Hospital, Internal Medicine
  • West Roxbury Veterans Administration Medical Center, Chief Medical Resident

Medical School

  • New York University

Recent Awards

  • Baruj Benacerraf Fellow, DFCI 1997
  • Scholar for Clinical Research, Leukemia Society of America 1999
  • Brian O'Dell Memorial Research Award 2001
  • Lee M. Nadler "Extra Mile" Award, DFCI 2004

Research

    Immunomodulation and Hematopoietic Stem Cell Transplantation

    The focus of our research for the past decade has been the development of treatment strategies to modulate the immune system of patients with cancer. These efforts are based on studies of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for hematologic malignancies. Although allogeneic transplantation can cure a proportion of these individuals, success is limited by transplant-related complications such as graft-versus-host disease (GVHD). It has long been recognized that T lymphocytes from the donor marrow play a pivotal role in the pathogenesis of GVHD. In patients undergoing HSCT, depleting donor marrow T cells with an antibody to a T cell surface structure results in a dramatic decrease in the incidence of GVHD. This approach also eliminates the need for immune-suppressive medications. These agents can be toxic, causing organ damage and increasing susceptibility to infection. Recently we have explored strategies to selectively infuse CD8+ depleted lymphocytes in hopes of prompting graft-versus-leukemia (GVL) activity without producing GVHD. We validated this strategy in a randomized trial of CD8-depleted donor lymphocyte infusions after T cell-depleted allotransplantation, and are now conducting further trials on CD8 depletion. While T cell depletion reduces GVHD, its effect on immune reactivity may lead to an increased risk of relapse of certain leukemias after transplantation. Preserving and restoring this GVL activity without compromising safety is a major thrust of our clinical and laboratory research. Working within the Cell Manipulation Core Facility, we have begun to identify specific T cell populations that may play a critical role in mediating antileukemia activity. We are exploring the role of regulatory T cells (Tregs) in the development of GVHD and GVL reactions, and have initiated a clinical trial to augment GVL reactivity using an antibody to CTLA4Ig, a molecule that controls immune reactions.We are also investigating vaccination strategies for preventing relapse in allogeneic transplant patients. Previously, in collaboration with Dr. Glenn Dranoff, we found that vaccination with irradiated autologous tumor cells - genetically engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF) - induced histologic, cellular, and humoral evidence of autologous antitumor immunity in nontransplant patients. We are combining vaccine approaches with the administration of allogeneic donor stem cells in hopes of inducing a synergistic antileukemia effect.

    Publications

      • Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024 Mar 05. View in: Pubmed

      • Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024 Feb 27; 8(4):978-990. View in: Pubmed

      • Coordinated Immune Cell Networks in the Bone Marrow Microenvironment Define the Graft versus Leukemia Response with Adoptive Cellular Therapy. bioRxiv. 2024 Feb 12. View in: Pubmed

      • Integrative genotyping of cancer and immune phenotypes by long-read sequencing. Nat Commun. 2024 Jan 02; 15(1):32. View in: Pubmed

      • Clinical Outcomes and Evolution of Clonal Hematopoiesis in Patients with Newly Diagnosed Multiple Myeloma. Cancer Res Commun. 2023 Dec 18; 3(12):2560-2571. View in: Pubmed

      • The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation. Expert Rev Hematol. 2023 Jul-Dec; 16(12):943-962. View in: Pubmed

      • Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401. Clin Cancer Res. 2023 Dec 01; 29(23):4784-4796. View in: Pubmed

      • Opportunistic Infections in Patients Receiving Post-Transplantation Cyclophosphamide: Impact of Haploidentical versus Unrelated Donor Allograft. Transplant Cell Ther. 2024 Feb; 30(2):233.e1-233.e14. View in: Pubmed

      • Immune Control in Repeated Babesia microti Infection in a Patient With B-Cell Deficiency. Open Forum Infect Dis. 2024 Jan; 11(1):ofad568. View in: Pubmed

      • AKI treated with kidney replacement therapy in critically Ill allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2024 02; 59(2):178-188. View in: Pubmed

      • Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2023 Aug 29; 42(8):113011. View in: Pubmed

      • Posttransplant cyclophosphamide vs tacrolimus-based GVHD prophylaxis: lower incidence of relapse and chronic GVHD. Blood Adv. 2023 08 08; 7(15):3903-3915. View in: Pubmed

      • Cytokine release syndrome in haploidentical stem cell transplant may impact T-cell recovery and relapse. Blood Adv. 2023 08 08; 7(15):4080-4088. View in: Pubmed

      • Cutaneous Squamous-Cell Carcinoma after Treatment with Ruxolitinib or Belumosudil. N Engl J Med. 2023 Jul 13; 389(2):188-190. View in: Pubmed

      • Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 06 15; 141(24):2932-2943. View in: Pubmed

      • Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells. Blood Adv. 2023 06 13; 7(11):2431-2435. View in: Pubmed

      • Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv. 2023 06 13; 7(11):2309-2316. View in: Pubmed

      • Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia. Clin Cancer Res. 2023 06 01; 29(11):2034-2042. View in: Pubmed

      • Prediction of risk for myeloid malignancy in clonal hematopoiesis. NEJM Evid. 2023 May; 2(5). View in: Pubmed

      • Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease. Blood. 2023 04 13; 141(15):1817-1830. View in: Pubmed

      • Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings. Blood. 2023 04 13; 141(15):1884-1888. View in: Pubmed

      • Clinical Features of Acute Kidney Injury in the Early Post-Transplantation Period Following Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2023 07; 29(7):455.e1-455.e9. View in: Pubmed

      • Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation. Transplant Cell Ther. 2023 05; 29(5):337.e1-337.e5. View in: Pubmed

      • Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica. 2023 01 01; 108(1):98-109. View in: Pubmed

      • What a "harmless" antibiotic can teach us about GVL. Blood. 2022 12 08; 140(23):2420-2422. View in: Pubmed

      • Harmonizing Definitions for Diagnostic Criteria and Prognostic Assessment of Transplantation-Associated Thrombotic Microangiopathy: A Report on Behalf of the European Society for Blood and Marrow Transplantation, American Society for Transplantation and Cellular Therapy, Asia-Pacific Blood and Marrow Transplantation Group, and Center for International Blood and Marrow Transplant Research. Transplant Cell Ther. 2023 03; 29(3):151-163. View in: Pubmed

      • Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022 11 22; 6(22):5857-5865. View in: Pubmed

      • A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease. Blood Adv. 2022 11 08; 6(21):5786-5796. View in: Pubmed

      • Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. Haematologica. 2022 11 01; 107(11):2617-2629. View in: Pubmed

      • Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity. Clin Infect Dis. 2022 08 24; 75(1):e920-e923. View in: Pubmed

      • Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease. Blood Adv. 2022 08 09; 6(15):4392-4402. View in: Pubmed

      • Association of Polypharmacy and Potentially Inappropriate Medications With Frailty Among Older Adults With Blood Cancers. J Natl Compr Canc Netw. 2022 08; 20(8):915-923.e5. View in: Pubmed

      • Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML. Blood. 2022 06 16; 139(24):3546-3557. View in: Pubmed

      • Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022 06 21; 119(25):e2122379119. View in: Pubmed

      • Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 06 01; 132(11). View in: Pubmed

      • BET-bromodomain and EZH2 inhibitor-treated chronic GVHD mice have blunted germinal centers with distinct transcriptomes. Blood. 2022 05 12; 139(19):2983-2997. View in: Pubmed

      • Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. Transplant Cell Ther. 2022 08; 28(8):508.e1-508.e8. View in: Pubmed

      • Randomized controlled trial of geriatric consultation versus standard care in older adults with hematologic malignancies. Haematologica. 2022 05 01; 107(5):1172-1180. View in: Pubmed

      • GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 04 12; 6(7):2183-2194. View in: Pubmed

      • Naïve T-Cell Depletion to Prevent GVHD: Searching for a Better Mousetrap. J Clin Oncol. 2022 04 10; 40(11):1139-1141. View in: Pubmed

      • Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant. Blood Adv. 2022 01 11; 6(1):181-188. View in: Pubmed

      • Adding venetoclax to fludarabine/busulfan RIC transplant for high-risk MDS and AML is feasible, safe, and active. Blood Adv. 2021 12 28; 5(24):5536-5545. View in: Pubmed

      • Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. Blood Adv. 2021 12 14; 5(23):5140-5149. View in: Pubmed

      • Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. Haematologica. 2021 12 01; 106(12):3219-3222. View in: Pubmed

      • Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. J Clin Oncol. 2022 01 10; 40(2):189-201. View in: Pubmed

      • Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 11 09; 37(6):109992. View in: Pubmed

      • Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplant Cell Ther. 2021 12; 27(12):990.e1-990.e7. View in: Pubmed

      • HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis. Blood. 2021 07 22; 138(3):273-282. View in: Pubmed

      • Prognostic value of disease risk score versus gait speed in older adults with lymphoma. Leuk Lymphoma. 2021 12; 62(12):2882-2889. View in: Pubmed

      • Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 06 10; 137(23):3212-3217. View in: Pubmed

      • Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis. Transpl Infect Dis. 2021 Aug; 23(4):e13619. View in: Pubmed

      • Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 May; 56(5):1217. View in: Pubmed

      • HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. Blood. 2021 Apr 13. View in: Pubmed

      • Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 Apr; 35(4):1223. View in: Pubmed

      • Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial. Transplant Cell Ther. 2021 06; 27(6):483.e1-483.e6. View in: Pubmed

      • Outcomes for Patients With IDH-Mutated Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2021 06; 27(6):479.e1-479.e7. View in: Pubmed

      • Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2021 05; 27(5):433.e1-433.e8. View in: Pubmed

      • COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Adv. 2021 02 09; 5(3):861-871. View in: Pubmed

      • COVID-19-induced endotheliitis: emerging evidence and possible therapeutic strategies. Br J Haematol. 2021 04; 193(1):43-51. View in: Pubmed

      • Primum non nocere: allo-HSCT for AML in CR1. Blood. 2021 01 28; 137(4):438-439. View in: Pubmed

      • Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021 01 26; 5(2):352-364. View in: Pubmed

      • Randomized Study of enterade® to Reduce Diarrhea in Patients Receiving High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation. Asian Pac J Cancer Prev. 2021 Jan 01; 22(1):301-304. View in: Pubmed

      • Gait speed, survival, and recommended treatment intensity in older adults with blood cancer requiring treatment. Cancer. 2021 03 15; 127(6):875-883. View in: Pubmed

      • Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? Leukemia. 2021 04; 35(4):1166-1175. View in: Pubmed

      • Topical sirolimus for management of refractory oral chronic graft-versus-host disease. Oral Dis. 2021 09; 27(6):1451-1454. View in: Pubmed

      • Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. Sci Transl Med. 2020 09 16; 12(561). View in: Pubmed

      • Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant. 2021 05; 56(5):1006-1012. View in: Pubmed

      • Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Adv. 2020 09 08; 4(17):4113-4123. View in: Pubmed

      • Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. J Clin Invest. 2020 09 01; 130(9):4624-4636. View in: Pubmed

      • Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute. Blood Adv. 2020 07 14; 4(13):3205-3208. View in: Pubmed

      • Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996. View in: Pubmed

      • A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020 06 11; 135(24):2182-2191. View in: Pubmed

      • BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Adv. 2020 05 12; 4(9):1881-1893. View in: Pubmed

      • Defibrotide formulations contain (1?3)-ß-D-glucan that could influence clinical diagnostic testing. Bone Marrow Transplant. 2020 10; 55(10):2045-2046. View in: Pubmed

      • Pooled analysis of Day 100 survival for defibrotide-treated patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome and ventilator or dialysis dependence following haematopoietic cell transplantation. Br J Haematol. 2020 08; 190(4):583-587. View in: Pubmed

      • Inhibition of inositol kinase B controls acute and chronic graft-versus-host disease. Blood. 2020 01 02; 135(1):28-40. View in: Pubmed

      • Genetic Alterations at Diagnosis Predict Outcome of AML Patients Age 60 or Older Undergoing Allogeneic Transplantation in First Remission. Blood. 2019 Nov 13; 134(Supplement_1):48. View in: Pubmed

      • Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 03; 26(3):529-539. View in: Pubmed

      • A phase II study of reduced intensity double umbilical cord blood transplantation using fludarabine, melphalan, and low dose total body irradiation. Bone Marrow Transplant. 2020 04; 55(4):804-810. View in: Pubmed

      • Prophylactic, preemptive, and curative treatment for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a position statement from an international expert group. Bone Marrow Transplant. 2020 03; 55(3):485-495. View in: Pubmed

      • Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. Blood Adv. 2019 09 10; 3(17):2550-2561. View in: Pubmed

      • A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2020 05; 26(5):835-844. View in: Pubmed

      • Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell Lymphoma. Biol Blood Marrow Transplant. 2019 12; 25(12):2383-2387. View in: Pubmed

      • Checkpoint inhibition to prevent or treat relapse in allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2019 08; 54(Suppl 2):798-802. View in: Pubmed

      • Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation. Blood Adv. 2019 07 23; 3(14):2199-2204. View in: Pubmed

      • Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials Network/BMT CTN 0402). Biol Blood Marrow Transplant. 2019 11; 25(11):2143-2151. View in: Pubmed

      • Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies. Blood. 2019 07 25; 134(4):374-382. View in: Pubmed

      • Progression Risk Stratification of Asymptomatic Waldenström Macroglobulinemia. J Clin Oncol. 2019 06 01; 37(16):1403-1411. View in: Pubmed

      • Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):984-994. View in: Pubmed

      • Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease. Blood Adv. 2019 04 09; 3(7):969-979. View in: Pubmed

      • Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies. J Am Geriatr Soc. 2019 05; 67(5):889-897. View in: Pubmed

      • Targeting PI3Kd function for amelioration of murine chronic graft-versus-host disease. Am J Transplant. 2019 06; 19(6):1820-1830. View in: Pubmed

      • Whole blood RNA sequencing reveals a unique transcriptomic profile in patients with ARDS following hematopoietic stem cell transplantation. Respir Res. 2019 Jan 21; 20(1):15. View in: Pubmed

      • Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. Cancer Immunol Res. 2019 01; 7(1):100-112. View in: Pubmed

      • Evaluating the adverse effects of melphalan formulations. J Oncol Pharm Pract. 2019 Oct; 25(7):1631-1637. View in: Pubmed

      • Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2019 01 03; 133(1):94-99. View in: Pubmed

      • Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation. Biol Blood Marrow Transplant. 2019 01; 25(1):137-144. View in: Pubmed

      • Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. Biol Blood Marrow Transplant. 2018 11; 24(11):2216-2223. View in: Pubmed

      • Cytomegalovirus Infection Among Cord Blood Allogeneic Transplantation Recipients: Low Incidence of Cytomegalovirus Events without High-Dose Valacyclovir Prophylaxis. Biol Blood Marrow Transplant. 2018 10; 24(10):2164-2165. View in: Pubmed

      • Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch? Blood Adv. 2018 06 12; 2(11):1180-1186. View in: Pubmed

      • Can IL-15 superagonist ALTer GVL? Blood. 2018 06 07; 131(23):2511-2512. View in: Pubmed

      • Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer. 2018 10; 65(10):e27269. View in: Pubmed

      • Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Br J Haematol. 2018 06; 181(6):816-827. View in: Pubmed

      • Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2018 11; 24(11):2344-2353. View in: Pubmed

      • High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018 06 21; 131(25):2816-2825. View in: Pubmed

      • Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers. JAMA Oncol. 2018 05 01; 4(5):686-693. View in: Pubmed

      • Integrated genomic characterization of oral carcinomas in post-hematopoietic stem cell transplantation survivors. Oral Oncol. 2018 06; 81:1-9. View in: Pubmed

      • A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. Biol Blood Marrow Transplant. 2018 08; 24(8):1733-1740. View in: Pubmed

      • Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 06 21; 131(25):2836-2845. View in: Pubmed

      • Immunohistopathological characterization and the impact of topical immunomodulatory therapy in oral chronic graft-versus-host disease: A pilot study. Oral Dis. 2018 May; 24(4):580-590. View in: Pubmed

      • Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiol Biomarkers Prev. 2018 03; 27(3):345-347. View in: Pubmed

      • Reply to J.J. Boelens et al. J Clin Oncol. 2018 04 10; 36(11):1176-1177. View in: Pubmed

      • a1-Antitrypsin infusion for treatment of steroid-resistant acute graft-versus-host disease. Blood. 2018 03 22; 131(12):1372-1379. View in: Pubmed

      • Tyrosine kinase inhibitors and immune checkpoint blockade in allogeneic hematopoietic cell transplantation. Blood. 2018 03 08; 131(10):1073-1080. View in: Pubmed

      • Neurocognitive dysfunction in hematopoietic cell transplant recipients: expert review from the late effects and Quality of Life Working Committee of the CIBMTR and complications and Quality of Life Working Party of the EBMT. Bone Marrow Transplant. 2018 05; 53(5):535-555. View in: Pubmed

      • Bortezomib-based immunosuppression after reduced-intensity conditioning hematopoietic stem cell transplantation: randomized phase II results. Haematologica. 2018 03; 103(3):522-530. View in: Pubmed

      • Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):699-707. View in: Pubmed

      • Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation. Blood Adv. 2017 Nov 28; 1(25):2473-2482. View in: Pubmed

      • Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant. 2018 03; 24(3):514-520. View in: Pubmed

      • Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. Blood Adv. 2017 Nov 14; 1(24):2269-2279. View in: Pubmed

      • Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. Blood. 2017 12 28; 130(26):2889-2899. View in: Pubmed

      • Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. J Clin Oncol. 2017 Dec 20; 35(36):4003-4011. View in: Pubmed

      • Neurocognitive Dysfunction in Hematopoietic Cell Transplant Recipients: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Complications and Quality of Life Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2018 02; 24(2):228-241. View in: Pubmed

      • Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cell-Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2017 Sep 10; 35(26):3002-3009. View in: Pubmed

      • Oral health status and risk of bacteremia following allogeneic hematopoietic cell transplantation. Oral Surg Oral Med Oral Pathol Oral Radiol. 2017 Sep; 124(3):253-260. View in: Pubmed

      • An activated Th17-prone T cell subset involved in chronic graft-versus-host disease sensitive to pharmacological inhibition. JCI Insight. 2017 Jun 15; 2(12). View in: Pubmed

      • Phase 1 multicenter trial of brentuximab vedotin for steroid-refractory acute graft-versus-host disease. Blood. 2017 06 15; 129(24):3256-3261. View in: Pubmed

      • Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 07 06; 130(1):91-94. View in: Pubmed

      • Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation. Br J Haematol. 2017 07; 178(1):112-118. View in: Pubmed

      • Continuation of a Levonorgestrel Intrauterine Device During Hematopoietic Stem Cell Transplant: A Case Report. Anticancer Res. 2017 04; 37(4):1985-1987. View in: Pubmed

      • Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. Haematologica. 2017 07; 102(7):1185-1191. View in: Pubmed

      • Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study. Biol Blood Marrow Transplant. 2017 Jun; 23(6):997-1004. View in: Pubmed

      • PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. Blood. 2017 04 13; 129(15):2186-2197. View in: Pubmed

      • Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 03 09; 129(10):1380-1388. View in: Pubmed

      • Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma. J Clin Oncol. 2017 May 10; 35(14):1598-1605. View in: Pubmed

      • Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients. Cytotherapy. 2017 02; 19(2):272-284. View in: Pubmed

      • Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. JCI Insight. 2016 11 03; 1(18):e89278. View in: Pubmed

      • Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human Leukocyte Antigen-Matched Grafts. Biol Blood Marrow Transplant. 2017 01; 23(1):126-133. View in: Pubmed

      • Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant. 2017 01; 23(1):113-118. View in: Pubmed

      • Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. Br J Haematol. 2016 Dec; 175(5):841-850. View in: Pubmed

      • An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2016 11; 22(11):2084-2091. View in: Pubmed

      • Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. Blood. 2016 10 06; 128(14):1845-1853. View in: Pubmed

      • Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation for Lymphoma. Biol Blood Marrow Transplant. 2016 10; 22(10):1808-1815. View in: Pubmed

      • Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol. 2016 Nov; 175(3):496-504. View in: Pubmed

      • Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14; 375(2):143-53. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 07 11; 30(1):183. View in: Pubmed

      • Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 08 18; 128(7):1013-7. View in: Pubmed

      • A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. Haematologica. 2016 10; 101(10):1251-1259. View in: Pubmed

      • Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016 10; 122(19):3005-3014. View in: Pubmed

      • Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. Am J Hematol. 2016 08; 91(8):793-9. View in: Pubmed

      • Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2016 08; 22(8):1504-1510. View in: Pubmed

      • Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 07 07; 128(1):130-7. View in: Pubmed

      • The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer Cell. 2016 04 11; 29(4):574-586. View in: Pubmed

      • The effect of FLT3-ITD and NPM1 mutation on survival in intensively treated elderly patients with cytogenetically normal acute myeloid leukemia. Leuk Lymphoma. 2016 08; 57(8):1977-9. View in: Pubmed

      • Does quality of life impact the decision to pursue stem cell transplantation for elderly patients with advanced MDS? Bone Marrow Transplant. 2016 Aug; 51(8):1121-6. View in: Pubmed

      • Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. Blood. 2016 05 19; 127(20):2489-97. View in: Pubmed

      • An interactive video-based approach to diet education for patients posthematopoietic stem cell transplantation. J Clin Oncol. 2016 Mar; 34(7_suppl):183. View in: Pubmed

      • Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. Am J Hematol. 2016 Mar; 91(3):322-9. View in: Pubmed

      • Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016 Mar 31; 127(13):1656-65. View in: Pubmed

      • Infused total nucleated cell dose is a better predictor of transplant outcomes than CD34+ cell number in reduced-intensity mobilized peripheral blood allogeneic hematopoietic cell transplantation. Haematologica. 2016 Apr; 101(4):499-505. View in: Pubmed

      • The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016 Apr; 173(1):96-104. View in: Pubmed

      • Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years. Biol Blood Marrow Transplant. 2016 May; 22(5):910-8. View in: Pubmed

      • Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation. F1000Res. 2015; 4:1480. View in: Pubmed

      • Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood. 2016 Feb 04; 127(5):646-57. View in: Pubmed

      • Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015 Dec 10; 33(35):4167-75. View in: Pubmed

      • Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):80-5. View in: Pubmed

      • Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep; 100(9):1222-7. View in: Pubmed

      • A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1907-13. View in: Pubmed

      • Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation for Patients with High-Risk Lymphoma. Biol Blood Marrow Transplant. 2015 Sep; 21(9):1583-8. View in: Pubmed

      • Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease. Blood. 2015 Jun 25; 125(26):4085-94. View in: Pubmed

      • The utility of routine chest radiography in the initial evaluation of adult patients with febrile neutropenia patients undergoing HSCT. J Natl Compr Canc Netw. 2015 Feb; 13(2):184-9. View in: Pubmed

      • Absolute lymphocyte count recovery after allogeneic hematopoietic stem cell transplantation predicts clinical outcome. Biol Blood Marrow Transplant. 2015 May; 21(5):873-80. View in: Pubmed

      • Angiogenic cytokines are antibody targets during graft-versus-leukemia reactions. Clin Cancer Res. 2015 Mar 01; 21(5):1010-8. View in: Pubmed

      • Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015 Feb 01; 33(4):364-9. View in: Pubmed

      • Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant. 2015 Mar; 21(3):509-16. View in: Pubmed

      • Readmissions following umbilical cord blood stem cell transplantation. J Clin Oncol. 2014 Oct 20; 32(30_suppl):272. View in: Pubmed

      • Narrow-band UVB phototherapy for management of oral chronic graft-versus-host disease. Photodermatol Photoimmunol Photomed. 2015 Mar; 31(2):75-82. View in: Pubmed

      • Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest. 2014 Nov; 124(11):4867-76. View in: Pubmed

      • Outcomes and management strategies for graft failure after umbilical cord blood transplantation. Am J Hematol. 2014 Dec; 89(12):1097-101. View in: Pubmed

      • Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. Biol Blood Marrow Transplant. 2014 Dec; 20(12):2042-8. View in: Pubmed

      • Antiretroviral-free HIV-1 remission and viral rebound after allogeneic stem cell transplantation: report of 2 cases. Ann Intern Med. 2014 Sep 02; 161(5):319-27. View in: Pubmed

      • Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec; 89(12):1092-6. View in: Pubmed

      • Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 Sep 01; 32(25):2691-8. View in: Pubmed

      • A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1737-43. View in: Pubmed

      • Characterization of oral involvement in acute graft-versus-host disease. Biol Blood Marrow Transplant. 2014 Nov; 20(11):1717-21. View in: Pubmed

      • Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1516-21. View in: Pubmed

      • Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014 Sep; 99(9):1499-508. View in: Pubmed

      • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans. Blood. 2014 Jun 19; 123(25):3988-98. View in: Pubmed

      • Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014 Jun 05; 123(23):3664-71. View in: Pubmed

      • Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014 Jun; 20(6):858-64. View in: Pubmed

      • White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. Am J Hematol. 2014 Jun; 89(6):591-7. View in: Pubmed

      • Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Am J Hematol. 2014 Apr; 89(4):404-9. View in: Pubmed

      • Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 May; 20(5):668-75. View in: Pubmed

      • BK virus disease after allogeneic stem cell transplantation: a cohort analysis. Biol Blood Marrow Transplant. 2014 Apr; 20(4):564-70. View in: Pubmed

      • Prostaglandin E2 promotes survival of naive UCB T cells via the Wnt/ß-catenin pathway and alters immune reconstitution after UCBT. Blood Cancer J. 2014 Jan 17; 4:e178. View in: Pubmed

      • Isavuconazole treatment of a patient with disseminated mucormycosis. J Clin Microbiol. 2014 Mar; 52(3):1016-9. View in: Pubmed

      • Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion. Blood. 2014 Feb 27; 123(9):1412-21. View in: Pubmed

      • Live attenuated varicella-zoster vaccine in hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2014 Feb; 20(2):285-7. View in: Pubmed

      • Readmissions following allogeneic hematopoietic stem cell transplantation. J Clin Oncol. 2013 Nov; 31(31_suppl):265. View in: Pubmed

      • Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014 Mar; 20(3):295-308. View in: Pubmed

      • Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec; 19(12):1713-8. View in: Pubmed

      • Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013 Oct 24; 122(17):3074-81. View in: Pubmed

      • Sequence-based discovery of Bradyrhizobium enterica in cord colitis syndrome. N Engl J Med. 2013 Aug 08; 369(6):517-28. View in: Pubmed

      • Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. J Clin Invest. 2013 Sep; 123(9):3756-65. View in: Pubmed

      • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013 Aug 22; 122(8):1510-7. View in: Pubmed

      • Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2013 Sep; 19(9):1374-80. View in: Pubmed

      • Impact of physician assistants on the outcomes of patients with acute myelogenous leukemia receiving chemotherapy in an academic medical center. J Oncol Pract. 2013 Sep; 9(5):e228-33. View in: Pubmed

      • Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 03; 5(179):179ra43. View in: Pubmed

      • Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia. Biol Blood Marrow Transplant. 2013 Jun; 19(6):981-7. View in: Pubmed

      • Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis. 2013 Jun 01; 207(11):1694-702. View in: Pubmed

      • Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2013 May; 19(5):804-11. View in: Pubmed

      • KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013 Jul; 48(7):1000-2. View in: Pubmed

      • Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8. View in: Pubmed

      • Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013 Jan; 12(1):123-36. View in: Pubmed

      • Reducing unnecessary testing on admission in autologous stem cell transplant (SCT) patients. J Clin Oncol. 2012 Dec; 30(34_suppl):185. View in: Pubmed

      • Airway dilation in bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. Respir Med. 2013 Feb; 107(2):276-83. View in: Pubmed

      • Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: novel insights to pathogenesis, current status of treatment, and future directions. Biol Blood Marrow Transplant. 2013 Jan; 19(1 Suppl):S88-90. View in: Pubmed

      • Expression of a4ß7 integrin on memory CD8(+) T cells at the presentation of acute intestinal GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):598-603. View in: Pubmed

      • Low levels of 25-hydroxyvitamin D before allogeneic hematopoietic SCT correlate with the development of chronic GVHD. Bone Marrow Transplant. 2013 Apr; 48(4):593-7. View in: Pubmed

      • Long-term follow-up of reduced-intensity allogeneic stem cell transplantation for chronic lymphocytic leukemia: prognostic model to predict outcome. Leukemia. 2013 Feb; 27(2):362-9. View in: Pubmed

      • Comparative outcomes of donor graft CD34+ selection and immune suppressive therapy as graft-versus-host disease prophylaxis for patients with acute myeloid leukemia in complete remission undergoing HLA-matched sibling allogeneic hematopoietic cell transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3194-201. View in: Pubmed

      • Bortezomib-based graft-versus-host disease prophylaxis in HLA-mismatched unrelated donor transplantation. J Clin Oncol. 2012 Sep 10; 30(26):3202-8. View in: Pubmed

      • Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease. Ther Adv Hematol. 2012 Aug; 3(4):253-65. View in: Pubmed

      • Phase II trial of parathyroid hormone after double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1851-8. View in: Pubmed

      • A disease risk index for patients undergoing allogeneic stem cell transplantation. Blood. 2012 Jul 26; 120(4):905-13. View in: Pubmed

      • Expression of CD30 in patients with acute graft-versus-host disease. Blood. 2012 Jul 19; 120(3):691-6. View in: Pubmed

      • Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant. 2013 Jan; 48(1):146-7. View in: Pubmed

      • Cord-blood hematopoietic stem cell transplant confers an increased risk for human herpesvirus-6-associated acute limbic encephalitis: a cohort analysis. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1638-48. View in: Pubmed

      • Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes. Blood. 2012 Jun 07; 119(23):5591-8. View in: Pubmed

      • Does iron overload really matter in stem cell transplantation? Am J Hematol. 2012 Jun; 87(6):569-72. View in: Pubmed

      • Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50. View in: Pubmed

      • To induce, or not to induce, that is the (still unanswered) question. Biol Blood Marrow Transplant. 2012 Mar; 18(3):332-3. View in: Pubmed

      • Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. Biol Blood Marrow Transplant. 2012 Jan; 18(1 Suppl):S111-5. View in: Pubmed

      • Important drug interactions in hematopoietic stem cell transplantation: what every physician should know. Biol Blood Marrow Transplant. 2012 Jul; 18(7):989-1006. View in: Pubmed

      • Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 01; 365(22):2055-66. View in: Pubmed

      • Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death. Sci Transl Med. 2011 Nov 23; 3(110):110ra118. View in: Pubmed

      • Reduced-intensity conditioning stem cell transplantation: comparison of double umbilical cord blood and unrelated donor grafts. Biol Blood Marrow Transplant. 2012 May; 18(5):805-12. View in: Pubmed

      • Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation. Blood. 2011 Dec 15; 118(25):6691-7. View in: Pubmed

      • The impact of geographic proximity to transplant center on outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 May; 18(5):708-15. View in: Pubmed

      • Low telomerase activity in CD4+ regulatory T cells in patients with severe chronic GVHD after hematopoietic stem cell transplantation. Blood. 2011 Nov 03; 118(18):5021-30. View in: Pubmed

      • Cord colitis syndrome in cord-blood stem-cell transplantation. N Engl J Med. 2011 Sep 01; 365(9):815-24. View in: Pubmed

      • Immune reconstitution after double umbilical cord blood stem cell transplantation: comparison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):565-74. View in: Pubmed

      • Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012 May; 18(5):690-7. View in: Pubmed

      • Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15; 92(3):359-65. View in: Pubmed

      • Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Apr; 18(4):575-83. View in: Pubmed

      • Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. Biol Blood Marrow Transplant. 2012 Feb; 18(2):280-8. View in: Pubmed

      • Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 Dec; 17(12):1796-803. View in: Pubmed

      • Oral epithelial dysplasia and squamous cell carcinoma following allogeneic hematopoietic stem cell transplantation: clinical presentation and treatment outcomes. Bone Marrow Transplant. 2011 Jun; 46(6):884-91. View in: Pubmed

      • Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011 Jun 23; 117(25):6963-70. View in: Pubmed

      • Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011 Apr; 121(4):1574-84. View in: Pubmed

      • Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. Biol Blood Marrow Transplant. 2011 Sep; 17(9):1343-51. View in: Pubmed

      • (90)Y-ibritumomab tiuxetan followed by reduced-intensity conditioning and allo-SCT in patients with advanced follicular lymphoma. Bone Marrow Transplant. 2011 Dec; 46(12):1503-9. View in: Pubmed

      • A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome. Ann Oncol. 2011 Jul; 22(7):1608-1613. View in: Pubmed

      • Invasive fungal disease after remote inoculation in transplant recipients. Clin Infect Dis. 2011 Jan 01; 52(1):e7-10. View in: Pubmed

      • Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1196-204. View in: Pubmed

      • Active immunotherapy induces antibody responses that target tumor angiogenesis. Cancer Res. 2010 Dec 15; 70(24):10150-60. View in: Pubmed

      • Allelic variations in CYP2B6 and CYP2C19 and survival of patients receiving cyclophosphamide prior to myeloablative hematopoietic stem cell transplantation. Am J Hematol. 2010 Dec; 85(12):967-71. View in: Pubmed

      • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011 Feb 17; 117(7):2275-83. View in: Pubmed

      • Seroprotective titers against 2009 H1N1 influenza A virus after vaccination in allogeneic hematopoietic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011 Mar; 17(3):434-8. View in: Pubmed

      • Syngeneic donor hematopoietic stem cell transplantation is associated with high rates of engraftment syndrome. Biol Blood Marrow Transplant. 2011 Mar; 17(3):421-8. View in: Pubmed

      • Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol Blood Marrow Transplant. 2011 Jun; 17(6):852-60. View in: Pubmed

      • CTLA-4 blockade following relapse of malignancy after allogeneic stem cell transplantation is associated with T cell activation but not with increased levels of T regulatory cells. Biol Blood Marrow Transplant. 2011 May; 17(5):682-92. View in: Pubmed

      • Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis. Bone Marrow Transplant. 2011 May; 46(5):659-67. View in: Pubmed

      • Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010 Jul; 11(7):653-60. View in: Pubmed

      • Graft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion. Clin Cancer Res. 2010 May 15; 16(10):2729-39. View in: Pubmed

      • Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May; 120(5):1479-93. View in: Pubmed

      • Prediction of veno-occlusive disease using biomarkers of endothelial injury. Biol Blood Marrow Transplant. 2010 Aug; 16(8):1180-5. View in: Pubmed

      • Donor-derived second hematologic malignancies after cord blood transplantation. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1025-31. View in: Pubmed

      • Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial. Biol Blood Marrow Transplant. 2010 Jul; 16(7):1005-17. View in: Pubmed

      • Diverse patterns of T-cell response against multiple newly identified human Y chromosome-encoded minor histocompatibility epitopes. Clin Cancer Res. 2010 Mar 01; 16(5):1642-51. View in: Pubmed

      • Outcome of allo-SCT for women with MDS or AML occurring after breast cancer therapy. Bone Marrow Transplant. 2010 Nov; 45(11):1611-7. View in: Pubmed

      • Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated B-cell antigens. Cancer Res. 2010 Feb 15; 70(4):1344-55. View in: Pubmed

      • The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of follicular lymphoma: an evidence-based review. Biol Blood Marrow Transplant. 2010 Apr; 16(4):443-68. View in: Pubmed

      • Clearance of CMV viremia and survival after double umbilical cord blood transplantation in adults depends on reconstitution of thymopoiesis. Blood. 2010 May 20; 115(20):4111-9. View in: Pubmed

      • Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. Cancer Res. 2010 Feb 01; 70(3):906-15. View in: Pubmed

      • Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age. Biol Blood Marrow Transplant. 2010 Jun; 16(6):792-800. View in: Pubmed

      • Donor-recipient mismatch for common gene deletion polymorphisms in graft-versus-host disease. Nat Genet. 2009 Dec; 41(12):1341-4. View in: Pubmed

      • Combined topical dexamethasone/tacrolimus therapy for management of oral chronic GVHD. Bone Marrow Transplant. 2010 Jun; 45(6):1062-7. View in: Pubmed

      • Multicenter validation study of a transplantation-specific cytogenetics grouping scheme for patients with myelodysplastic syndromes. Bone Marrow Transplant. 2010 May; 45(5):877-85. View in: Pubmed

      • Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010 Feb; 16(2):157-68. View in: Pubmed

      • Oral chronic graft-versus-host disease scoring using the NIH consensus criteria. Biol Blood Marrow Transplant. 2010 Jan; 16(1):108-14. View in: Pubmed

      • Bortezomib, tacrolimus, and methotrexate for prophylaxis of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation from HLA-mismatched unrelated donors. Blood. 2009 Oct 29; 114(18):3956-9. View in: Pubmed

      • Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci U S A. 2009 Sep 15; 106(37):15825-30. View in: Pubmed

      • Up-Regulation of alpha4beta7 integrin on peripheral T cell subsets correlates with the development of acute intestinal graft-versus-host disease following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Sep; 15(9):1066-76. View in: Pubmed

      • Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and mini-methotrexate (Tac/Sir/MTX) as acute graft-versus-host disease prophylaxis after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2009 Jul; 15(7):844-50. View in: Pubmed

      • Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 Jun 10; 301(22):2349-61. View in: Pubmed

      • Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement. Biol Blood Marrow Transplant. 2009 Jul; 15(7):777-84. View in: Pubmed

      • Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Mar; 15(3):382-8. View in: Pubmed

      • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16; 113(16):3865-74. View in: Pubmed

      • High-resolution HLA matching in double-umbilical-cord-blood reduced-intensity transplantation in adults. Transfusion. 2009 May; 49(5):995-1002. View in: Pubmed

      • Finding the right academic job. Hematology Am Soc Hematol Educ Program. 2009; 729-33. View in: Pubmed

      • Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. Blood. 2009 Feb 19; 113(8):1681-8. View in: Pubmed

      • Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning. J Clin Oncol. 2008 Dec 10; 26(35):5767-74. View in: Pubmed

      • Variation in supportive care practices in hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008 Nov; 14(11):1231-8. View in: Pubmed

      • CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 Feb 12; 113(7):1581-8. View in: Pubmed

      • Low dose interleukin-2 following intensification therapy with high dose cytarabine for acute myelogenous leukemia in first complete remission. Am J Hematol. 2008 Oct; 83(10):771-7. View in: Pubmed

      • Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood. 2008 Dec 01; 112(12):4425-31. View in: Pubmed

      • Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008 Sep; 21(3):455-66. View in: Pubmed

      • Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2008 Aug; 14(8):920-6. View in: Pubmed

      • Immune modulation and chronic graft-versus-host disease. Bone Marrow Transplant. 2008 Aug; 42 Suppl 1:S66-S69. View in: Pubmed

      • Recurrent acute promyelocytic leukemia presenting as a sacral nerve root mass. J Clin Oncol. 2008 Jul 01; 26(19):3279-81. View in: Pubmed

      • Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant. 2008 Apr; 14(4):418-25. View in: Pubmed

      • Individual physician practice variation in hematopoietic cell transplantation. J Clin Oncol. 2008 May 01; 26(13):2162-70. View in: Pubmed

      • Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb; 14(2):197-207. View in: Pubmed

      • Clinical evaluation of oral chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2008 Jan; 14(1):110-5. View in: Pubmed

      • Chronic graft-versus-host disease: how can we release Prometheus? Biol Blood Marrow Transplant. 2008 Jan; 14(1 Suppl 1):142-50. View in: Pubmed

      • Preinfusion variables predict the predominant unit in the setting of reduced-intensity double cord blood transplantation. Bone Marrow Transplant. 2008 Mar; 41(6):523-9. View in: Pubmed

      • A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan; 14(1):28-35. View in: Pubmed

      • High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15; 13(20):6107-14. View in: Pubmed

      • Post-transplant acute limbic encephalitis: clinical features and relationship to HHV6. Neurology. 2007 Jul 10; 69(2):156-65. View in: Pubmed

      • Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 Aug; 40(3):209-17. View in: Pubmed

      • Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2007 May; 5(5):474-96. View in: Pubmed

      • Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007 Apr 01; 109(7):3108-14. View in: Pubmed

      • Sirolimus-based graft-versus-host disease prophylaxis protects against cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation: a cohort analysis. Blood. 2007 Jul 15; 110(2):490-500. View in: Pubmed

      • Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation. Biol Blood Marrow Transplant. 2007 Jun; 13(6):655-64. View in: Pubmed

      • High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96. View in: Pubmed

      • Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007 May 15; 109(10):4586-8. View in: Pubmed

      • Double unrelated reduced-intensity umbilical cord blood transplantation in adults. Biol Blood Marrow Transplant. 2007 Jan; 13(1):82-9. View in: Pubmed

      • Differential epitope mapping of antibodies to PDC-E2 in patients with hematologic malignancies after allogeneic hematopoietic stem cell transplantation and primary biliary cirrhosis. Blood. 2007 Mar 01; 109(5):2001-7. View in: Pubmed

      • Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1056-64. View in: Pubmed

      • Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant. 2006 Oct; 12(10):1047-55. View in: Pubmed

      • Quality of life associated with acute and chronic graft-versus-host disease. Bone Marrow Transplant. 2006 Aug; 38(4):305-10. View in: Pubmed

      • HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant. 2006 May; 37(9):845-50. View in: Pubmed

      • IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo. Blood. 2006 Sep 01; 108(5):1571-9. View in: Pubmed

      • Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15; 108(2):756-62. View in: Pubmed

      • Chronic myelogenous leukemia. J Natl Compr Canc Netw. 2005 Nov; 3(6):732-55. View in: Pubmed

      • Immunization using autologous dendritic cells pulsed with the melanoma-associated antigen gp100-derived G280-9V peptide elicits CD8+ immunity. Clin Cancer Res. 2005 Nov 01; 11(21):7692-9. View in: Pubmed

      • Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106(13):4389-96. View in: Pubmed

      • Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Aug; 11(8):571-5. View in: Pubmed

      • Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Jul; 11(7):551-7. View in: Pubmed

      • Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15; 106(8):2903-11. View in: Pubmed

      • Graft-versus-leukemia target antigens in chronic myelogenous leukemia are expressed on myeloid progenitor cells. Clin Cancer Res. 2005 Jun 15; 11(12):4504-11. View in: Pubmed

      • Mucositis after allogeneic hematopoietic stem cell transplantation: a cohort study of methotrexate- and non-methotrexate-containing graft-versus-host disease prophylaxis regimens. Biol Blood Marrow Transplant. 2005 May; 11(5):383-8. View in: Pubmed

      • Protective antibody responses to pneumococcal conjugate vaccine after autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Mar; 11(3):213-22. View in: Pubmed

      • Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res. 2005 Feb; 15(1):77-82. View in: Pubmed

      • Severe hypercholesterolemia mediated by lipoprotein X in patients with chronic graft-versus-host disease of the liver. Bone Marrow Transplant. 2005 Jan; 35(1):85-9. View in: Pubmed

      • Routine screening for psychosocial distress following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005 Jan; 35(1):77-83. View in: Pubmed

      • Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 01; 105(7):2973-8. View in: Pubmed

      • Renal failure associated with cancer and its treatment: an update. J Am Soc Nephrol. 2005 Jan; 16(1):151-61. View in: Pubmed

      • Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplant. 2004 Dec; 34(11):987-94. View in: Pubmed

      • Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005 Feb 15; 105(4):1810-4. View in: Pubmed

      • Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease. Clin Cancer Res. 2004 Aug 01; 10(15):5065-71. View in: Pubmed

      • CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant. 2004 Jul; 34(2):123-8. View in: Pubmed

      • Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004 Sep 01; 104(5):1559-64. View in: Pubmed

      • Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 May; 10(5):328-36. View in: Pubmed

      • Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104(4):1224-6. View in: Pubmed

      • Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19; 199(8):1133-42. View in: Pubmed

      • Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44(2):253-61. View in: Pubmed

      • Graft-versus-host disease of the vulva and/or vagina: diagnosis and treatment. Biol Blood Marrow Transplant. 2003 Dec; 9(12):760-5. View in: Pubmed

      • Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. 2003 Dec; 32(12):1145-51. View in: Pubmed

      • Fatal hepatic necrosis following imatinib mesylate therapy. Blood. 2003 Nov 01; 102(9):3455-6. View in: Pubmed

      • Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 01; 103(1):353-9. View in: Pubmed

      • Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003 Sep 01; 21(17):3343-50. View in: Pubmed

      • Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood. 2003 Oct 15; 102(8):2768-76. View in: Pubmed

      • Optimistic expectations and survival after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2003 Jun; 9(6):389-96. View in: Pubmed

      • Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood. 2003 Sep 01; 102(5):1578-82. View in: Pubmed

      • Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 01; 102(5):1601-5. View in: Pubmed

      • Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003 Apr 15; 100(8):4712-7. View in: Pubmed

      • MUC1-like tandem repeat proteins are broadly immunogenic in cancer patients. Cancer Immun. 2003 Mar 17; 3:3. View in: Pubmed

      • Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3398-403. View in: Pubmed

      • Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. Leuk Lymphoma. 2002 Dec; 43(12):2281-9. View in: Pubmed

      • Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs. Blood. 2002 Oct 15; 100(8):2697-702. View in: Pubmed

      • CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res. 2002 Oct 01; 62(19):5517-5522. View in: Pubmed

      • Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood. 2003 Feb 01; 101(3):831-6. View in: Pubmed

      • A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. Blood. 2003 Jan 01; 101(1):363-9. View in: Pubmed

      • Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood. 2002 Dec 15; 100(13):4337-43. View in: Pubmed

      • Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. Blood. 2002 Nov 15; 100(10):3479-82. View in: Pubmed

      • Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 2002 Jul 15; 74(1):49-54. View in: Pubmed

      • Infusion of CD4+ donor lymphocytes induces the expansion of CD8+ donor T cells with cytolytic activity directed against recipient hematopoietic cells. Clin Cancer Res. 2002 Jul; 8(7):2052-60. View in: Pubmed

      • Immunologic effects of prophylactic donor lymphocyte infusion after allogeneic marrow transplantation for multiple myeloma. Blood. 2002 Jun 15; 99(12):4610-7. View in: Pubmed

      • Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. Br J Haematol. 2002 Jun; 117(4):828-34. View in: Pubmed

      • Phase II study of paclitaxel and carboplatin for malignant melanoma. Am J Clin Oncol. 2002 Jun; 25(3):283-6. View in: Pubmed

      • ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. Proc Natl Acad Sci U S A. 2002 May 14; 99(10):6919-24. View in: Pubmed

      • A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002 Mar; 29(5):373-7. View in: Pubmed

      • Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002; 8(11):625-32. View in: Pubmed

      • Comparable outcome with T-cell-depleted unrelated-donor versus related-donor allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(11):601-7. View in: Pubmed

      • Development and validation of a scale to measure symptoms of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2002; 8(8):444-52. View in: Pubmed

      • Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2002; 8(3):139-44. View in: Pubmed

      • The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood. 2001 Dec 01; 98(12):3192-204. View in: Pubmed

      • Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. Blood. 2001 Aug 15; 98(4):1116-21. View in: Pubmed

      • T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood. 2001 Aug 15; 98(4):934-9. View in: Pubmed

      • CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 2001 Jun 19; 98(13):7492-7. View in: Pubmed

      • A CD4+ T cell clone selected from a CML patient after donor lymphocyte infusion recognizes BCR-ABL breakpoint peptides but not tumor cells. Transplantation. 2001 Apr 27; 71(8):1131-7. View in: Pubmed

      • CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15; 19(4):1152-9. View in: Pubmed

      • Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001; 7(4):223-9. View in: Pubmed

      • Recovery after stem-cell transplantation for hematologic diseases. J Clin Oncol. 2001 Jan 01; 19(1):242-52. View in: Pubmed

      • NCCN Practice Guidelines for Chronic Myelogenous Leukemia. Oncology (Williston Park). 2000 Nov; 14(11A):229-40. View in: Pubmed

      • Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. J Clin Invest. 2000 Sep; 106(5):705-14. View in: Pubmed

      • Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma. Cancer J. 2000 May-Jun; 6(3):139-45. View in: Pubmed

      • Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. Bone Marrow Transplant. 2000 Mar; 25(6):623-32. View in: Pubmed

      • Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. Blood. 2000 Jan 01; 95(1):352-9. View in: Pubmed

      • Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma. Biol Blood Marrow Transplant. 2000; 6(4):375-86. View in: Pubmed

      • Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood. 1999 Nov 15; 94(10):3325-33. View in: Pubmed

      • Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1999 Oct; 17(10):3128-35. View in: Pubmed

      • Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion. J Clin Oncol. 1999 Feb; 17(2):561-8. View in: Pubmed

      • Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999; 5(4):262-8. View in: Pubmed

      • Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998 Oct 27; 95(22):13141-6. View in: Pubmed

      • Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998 Oct 15; 92(8):2725-9. View in: Pubmed

      • Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood. 1998 Aug 01; 92(3):737-44. View in: Pubmed

      • CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Bone Marrow Transplant. 1998 Jun; 21(12):1177-81. View in: Pubmed

      • Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood. 1998 May 15; 91(10):3671-80. View in: Pubmed

      • IGIV: a potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplant. 1998 Apr; 21(7):739-42. View in: Pubmed

      • High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol. 1998 Jan; 16(1):13-8. View in: Pubmed

      • Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. Blood. 1997 Dec 15; 90(12):4996-5001. View in: Pubmed

      • Guillain-Barré syndrome following allogeneic bone marrow transplantation. Neurology. 1997 Dec; 49(6):1711-4. View in: Pubmed

      • Altered tyrosine phosphorylation via the very late antigen (VLA)/beta1 integrin stimulation is associated with impaired T-cell signaling through VLA-4 after allogeneic bone marrow transplantation. Blood. 1997 Nov 15; 90(10):4222-9. View in: Pubmed

      • In vivo adsorption of isohemagglutinins with fresh frozen plasma in major ABO-incompatible bone marrow transplantation. Biol Blood Marrow Transplant. 1997 Nov; 3(5):267-72. View in: Pubmed

      • Characterization of T cell repertoire in patients with graft-versus-leukemia after donor lymphocyte infusion. J Clin Invest. 1997 Aug 15; 100(4):855-66. View in: Pubmed

      • CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission. Blood. 1997 Apr 15; 89(8):3039-47. View in: Pubmed

      • CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Biol Blood Marrow Transplant. 1997 Apr; 3(1):11-7. View in: Pubmed

      • Donor lymphocyte infusions: the door is open. J Clin Oncol. 1997 Feb; 15(2):416-7. View in: Pubmed

      • Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. Clin Cancer Res. 1997 Jan; 3(1):17-24. View in: Pubmed

      • A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. Hum Gene Ther. 1997 Jan 01; 8(1):111-23. View in: Pubmed

      • Prevention of transmission of hepatitis C virus in bone marrow transplantation by treating the donor with alpha-interferon. Transplantation. 1996 Nov 15; 62(9):1358-60. View in: Pubmed

      • High-dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. Blood. 1996 Oct 01; 88(7):2780-6. View in: Pubmed

      • Defective activation of mitogen-activated protein kinase after allogeneic bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2334-41. View in: Pubmed

      • Eradication of polymerase chain reaction-detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. Blood. 1996 Sep 15; 88(6):2228-35. View in: Pubmed

      • R24 anti-GD3 ganglioside antibody can induce costimulation and prevent the induction of alloantigen-specific T cell clonal anergy. Eur J Immunol. 1996 Sep; 26(9):2149-54. View in: Pubmed

      • Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. Bone Marrow Transplant. 1996 Jun; 17(6):1051-6. View in: Pubmed

      • Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2. Clin Cancer Res. 1996 Mar; 2(3):493-9. View in: Pubmed

      • A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood. 1995 Apr 01; 85(7):1881-7. View in: Pubmed

      • Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Leuk Lymphoma. 1995 Mar; 17(1-2):87-93. View in: Pubmed

      • Recombinant interleukin-2 infusions and decreased IgG2 subclass concentrations. Blood. 1995 Feb 15; 85(4):925-8. View in: Pubmed

      • Differential CD26-mediated activation of the CD3 and CD2 pathways after CD6-depleted allogeneic bone marrow transplantation. Blood. 1995 Feb 15; 85(4):1132-7. View in: Pubmed

      • Immunomodulatory effects of donor lymphocyte infusions following allogeneic bone marrow transplantation. J Clin Apher. 1995; 10(3):139-43. View in: Pubmed

      • Myelodysplastic syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol. 1994 Dec; 12(12):2535-42. View in: Pubmed

      • Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia. Blood. 1994 Oct 01; 84(7):2109-14. View in: Pubmed

      • Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood. 1994 Aug 01; 84(3):964-71. View in: Pubmed

      • Prolonged impairment of very late activating antigen-mediated T cell proliferation via the CD3 pathway after T cell-depleted allogeneic bone marrow transplantation. J Clin Invest. 1994 Aug; 94(2):481-8. View in: Pubmed

      • The phenotype and reconstitution of immunoregulatory T cell subsets after T cell-depleted allogeneic and autologous bone marrow transplantation. Transplantation. 1994 May 27; 57(10):1465-73. View in: Pubmed

      • A phase II study of continuous infusion recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma in first remission. Blood. 1994 May 01; 83(9):2707-14. View in: Pubmed

      • The effect of minor ABO mismatches on the incidence of graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation. 1994 Mar 15; 57(5):780. View in: Pubmed

      • Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood. 1993 Nov 01; 82(9):2790-6. View in: Pubmed

      • Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. Blood. 1993 Oct 15; 82(8):2568-76. View in: Pubmed

      • Prediction of graft-versus-host disease by phenotypic analysis of early immune reconstitution after CD6-depleted allogeneic bone marrow transplantation. Blood. 1993 Oct 01; 82(7):2216-23. View in: Pubmed

      • Monoclonal antibody-purged autologous bone marrow transplantation in adults with acute lymphoblastic leukemia at high risk of relapse. Bone Marrow Transplant. 1993 Sep; 12(3):243-51. View in: Pubmed

      • Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood. 1993 Aug 15; 82(4):1366-76. View in: Pubmed

      • Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol. 1993 May; 11(5):931-6. View in: Pubmed

      • Selective T cell depletion of donor allogeneic marrow with anti-CD6 monoclonal antibody: rationale and results. Bone Marrow Transplant. 1993; 12 Suppl 3:S7-10. View in: Pubmed

      • Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest. 1993 Jan; 91(1):123-32. View in: Pubmed

      • Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992 Jul; 10(7):1191-200. View in: Pubmed

      • Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood. 1992 May 01; 79(9):2229-36. View in: Pubmed

      • Immune-mediated cytopenia following bone marrow transplantation. Case reports and review of the literature. Medicine (Baltimore). 1992 Mar; 71(2):73-83. View in: Pubmed

      • Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992 Mar 01; 175(3):779-88. View in: Pubmed

      • Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood. 1992 Jan 15; 79(2):517-26. View in: Pubmed

      • Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991 Dec; 52(6):1014-9. View in: Pubmed

      • Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity. J Clin Oncol. 1991 Dec; 9(12):2110-9. View in: Pubmed

      • Clinical significance of bcr-abl gene rearrangement detected by polymerase chain reaction after allogeneic bone marrow transplantation in chronic myelogenous leukemia. Blood. 1991 Nov 15; 78(10):2759-67. View in: Pubmed

      • Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. Bone Marrow Transplant. 1991 Aug; 8(2):143-5. View in: Pubmed

      • Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma. Blood. 1991 Jun 01; 77(11):2524-9. View in: Pubmed

      • Hemolytic-uremic syndrome following bone marrow transplantation in adults for hematologic malignancies. Blood. 1991 Apr 15; 77(8):1837-44. View in: Pubmed

      • Monoclonal antibody-purged autologous bone marrow transplantation therapy for multiple myeloma. Blood. 1991 Feb 15; 77(4):712-20. View in: Pubmed

      • Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant. 1991 Jan; 7(1):23-33. View in: Pubmed

      • Autoimmune pancytopenia following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990 Dec; 6(6):445-7. View in: Pubmed

      • Acute and chronic pulmonary complications following autologous bone marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant. 1990 Nov; 6(5):329-31. View in: Pubmed

      • T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications. Blood. 1990 Jul 01; 76(1):235-44. View in: Pubmed

      • Reconstitution of T-cell function after CD6-depleted allogeneic bone marrow transplantation. Blood. 1990 May 15; 75(10):2076-84. View in: Pubmed

      • Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol. 1990 May; 8(5):784-91. View in: Pubmed

      • High-dose cytosine arabinoside in relapsed and refractory non-Hodgkin's lymphoma. Limited role as a single agent. Cancer. 1989 Nov 15; 64(10):2014-8. View in: Pubmed

      Locations

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Directions

      Dana-Farber Cancer Institute

      Location Avtar

      Dana-Farber Cancer Institute

      450 Brookline Avenue Boston, MA 02215
      Get Direction
      42.3374, -71.1082

      Ratings and Comments

      Robert J. Soiffer, MD

      About Our Ratings

      Physician Star Rating Comment Block